Importantly, “pathway in the cancer” ranked first, and SMAD2 as one of genes in this pathway was further investigated since besides TargetScan prediction, SMAD2 also got strongly-evidenced interactions with miR-155-5p by miRTarBase [30], an experimentally validated microRNA-target interactions database, and several reports indicate a promotional effect of SMAD2 on GC progression [31–33]. Here, SMAD2 is linked to cancer.